Compare · GLP-1 agonist
CagriSema vs Ecnoglutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| CagriSema | Ecnoglutide | |
|---|---|---|
| Evidence | Strong human | Preliminary human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An investigational once-weekly fixed combination of cagrilintide (an amylin analog) plus semaglutide (a GLP-1 drug) with large peer-reviewed Phase 3 weight-loss data, but no approval yet and a failed head-to-head against tirzepatide. | A long-acting, cAMP-biased GLP-1 receptor agonist approved in China for type 2 diabetes and weight management, with genuine peer-reviewed Phase 3 data that is still confined to Chinese populations and not FDA-approved. |
| Full profile → | Full profile → |
CagriSema
CagriSema is one of the most heavily studied combination products in the obesity-drug pipeline, and also a useful case study in why "strong trial data" and "proven, approved, and better than the alternatives" are not the same thing. It is a once-weekly injectable that fixes two peptides into a…
Ecnoglutide
Ecnoglutide (development code XW003) is an injectable drug for type 2 diabetes and weight loss that belongs to the same broad GLP-1 receptor agonist family as semaglutide. It stands out for two reasons: its developer engineered it to be "cAMP-biased," a real and characterized pharmacological…